UnaCom Pharma Economic News Round Up

                                          3rd September- 9th September

Tuesday 4th September

Exox raises £35 million to advance Exosome Therapeutics 

Oxford based, Exox, received significant 'new investements' from GV (Google Ventures), Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis and a small number of private investors. Investment was also provided by exisitng investors, Oxford Sciences Innovation and Oxford University, who provided £10million into the company. The work that Exox is doing is developing their own  exosomes, which are the bodies natural vesicular delivery system, to allow a wide variety of drugs to reach previously inaccessible tissues such as crossing the blood brain barrier to deliver drugs to the Central Nervous System. The investment will be used to progress mutiple rare disease assests towards the clinic and develop the exosome drug platform.

Dechra Pharma moving on with Hard Brexit Plans 

Veterinary drug producer, Dechra Pharma, has announced on Monday, that it is moving ahead with its hard Brexit plans, stressing that the financial impacts should be 'immaterial' but spooking investors worried about revenues and operations. Shares of the company fell by 20%, to a 6 month low of 2,454 pence. The comapny said their primary concern was adressing the Brexit risk in the supply chain, with the company sayingt that the plans relate to a cost of £2million. These plans include transferring UK registered Marketing Authorisations for products that are sold in the EU to an EU entity and duplication of product release testing for products that are transferred between the UK and the EU.

Wednesday 5th September

By Cutting Agency Staff, NHS could save up to £480 million 

According to NHS improvement, if the NHS cut back on agency care it could save money to be used for front line care. The agency said that the £480 million could be directed into services and patient care, if trusts filled temporary vacancies with workers from a ‘staff bank’ instead of using expensive staffing agencies. It stressed that temporary staff cost on average more than 20% than those from the NHS, depsite doing the same job. NHS Improvement chief executive Ian Dalton, wants the NHS to implement a bank staff approach and only use agency staff as a last resort. The agency is calling for all trusts to take a 'bank first' approach and too cut agency cuts by 17% for 2018/19.

Thursday 4th September

Novo signs research and option deal with American Ossianix 

Novo has signed a research and option agreement with Ossianix, on a blood brain barrier delivery echnology for proteins in diabetes and other metabolic diseases. Under the terms of the deal, Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents able to cross the blood brain barrier to Novo, which will then take on their development and commercialisation. Ossianix will recieve upfront, pre clinical, clinical and commercial milestone payments. n addition, the Danish drugmaker has a buyout option for each product on pre-agreed financial terms. The financial details of the deal were not disclosed.

Friday 7th September

BTG buys Irish Med Group Novate 

Specialist healthcare BTG has bought Irish medical device group Novate in a deal worth potentially $150 million. Novate which is located in the Republic of Ireland, is focused on medical devices that help prevent of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events. Novata  has developed Sentry, the first bioconvertible inferior vena cava (IVC) filter, which in clinical trials showed no new symptomatic PE andno evidence of complications asscociated with other filters. BTG says it plans to introduce Sentry to the US, in the second half of 2018/19 and will sell it through its exisitng vascular sales force. Under the terms of the deal, BTG has already paid $20 million in cash to acquire Novate but could pay out and an extra $130 million if certain commercial and sales-related milestones are met.

Eli Lilly has poured £5 million into virtual lab pact with Imperial and UCL

Lily has provided £5 million to fund research into the more efficient manufacture of medicines, which, the parties note, could ultimately result in better and cheaper treatments for patients. The money  will be used to fund a virtual lab, led by Imperial, and will see researchers applying Process system Engineering methods to improve medicines manufacturing. This type of computer modelling which is already used in the petrochemical, chemicals and consumer goods industry has potential to increase efficiency, decrease wastage and resolve quality control issues across the manufacturing process.  


No comments:

Post a Comment

Coranavirus and its relationship with IP exclusivity

With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...